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301 Gender differences in life satisfaction of adolescent and adult
patients with cystic ﬁbrosis
T. Besier, L. Goldbeck. Child and Adolescent Psychiatry/Psychotherapy, University
Hospital, Ulm, Germany
Objective: The progression of cystic ﬁbrosis (CF) is more rapid in female patients
compared with males, in terms of a decline of pulmonary functioning and increased
mortality. Therefore it can be expected that female patients report worse quality
of life compared with male patients. Based on a model combining subjective
importance and satisfaction ratings we assessed gender speciﬁc patterns of life
satisfaction in patients with CF.
Methods: 474 patients with CF (M 28.4 years, SD 8.2 years; 52% female) ﬁlled
in the Questions on Life Satisfaction (FLZM-CF), a multidimensional instrument
measuring quality of life in eight general, eight health-related, and nine CF-speciﬁc
life domains. Gender differences were analysed by t-Tests for independent samples.
Results: In most dimension of life satisfaction no gender differences occurred.
However, female patients considered “energy/zest for life” (t(473) = −2.8, p = 0.05)
and “understanding by others” (t(471) = −4.07, p< 0.001) signiﬁcantly more im-
portant than males and were signiﬁcantly less satisﬁed with their “freedom
from anxiety” (t(471) = 3.76, p< 0.001), “freedom from aches/pains” (t(471) = 3.61,
p< 0.001) and “independence from help/care” (t(472) = 3.30, p = 0.001). Male pa-
tients were more satisﬁed with “dyspnea/cough” (t(471) = 5.19, p< 0.001). Females
showed signiﬁcantly lower weighted satisfaction scores than males in “freedom from
anxiety” (t(446) = 2.85, p = 0.005), “independence from help/care” (t(446) = 3.13,
p = 0.002), and in “dyspnea/cough” (t(445) = 4.80, p< 0.001).
Conclusions: There are only few gender-speciﬁc patterns of life satisfaction,
especially in some health-related aspects of life satisfaction. Both objective gender
differences in disease progression and gender-speciﬁc health perceptions might be
responsible for these ﬁndings.
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Aims: There is a paucity of research assessing the psychosocial impact of CF
on caregivers. The aims of this study are to: (1) assess anxiety and depression
in caregivers of children with CF; & (2) describe concurrent relations between
caregiver QOL and symptoms of anxiety and depression.
Method: 24 mothers of patients with CF participated in this study. Mothers
completed the Hospital Anxiety and Depression Scale (HADS) and Caregiver
Quality of Life Scale Cystic Fibrosis (CQOLCF), with higher scores indicating
poorer QOL. Data collection is ongoing and occurs during routine CF Clinic visits.
Results: Mothers reported clinical elevations in anxiety symptoms as follows:
8% = mild, 13% = moderate, 13% = severe; whereas, clinical elevations in
depressive symptoms were 13% = mild, 4% = moderate, and 4% = severe. Caregiver
quality of life was signiﬁcantly correlated with anxiety (r = 0.73, p< 0.001) and
depressive symptoms (r = 0.72, p< 0.001). Regression analyses predicting caregiver
quality of life and the association between parent and child anxiety and depression
will also be examined.
Conclusions: The results of this study reveal 34% and 21% of mothers of children
with CF reported signiﬁcant symptoms of anxiety and depression, respectively.
In addition, poor caregiver QOL was associated with increased depressive and
anxious symptoms. Healthcare teams generally focus on patient health and well-
being. However, these ﬁndings highlight the importance of assessing and treating
symptoms of anxiety and depression and QOL in mothers, as their psychosocial
functioning has the potential to signiﬁcantly impact the psychosocial functioning
of their child.
303 Predicting change in depression for parents of children with CF:
health and demographic factors
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Introduction: Elevations in depressive symptoms have been commonly reported by
parents of children with CF. The ﬁrst aim of this study was to assess depression in
parents of children with CF before and after an adherence intervention. The second
aim was to identify predictors of change in depression.
Methods: Data were derived from a multi-site intervention study at three CF Cen-
ters in Florida. Children with CF ages 1−11 years and their parents participated. A
total of 88 families were enrolled. Parents completed the Center for Epidemiological
Studies–Depression Scale (CES-D), at Baseline and Post-Intervention.
Results: At Baseline, 30% of parents met the clinical cutoff for depression on the
CES-D (mean = 11.79) with 23.6% above the cutoff at follow-up (mean = 10.09).
Demographic characteristics such as maternal education and family income were
not related to depression. In contrast, pulmonary functioning was signiﬁcantly
related to depression at both time points, with better lung function associated with
more depression. Analyses of the stability of depressive symptoms indicated that
11.6% of parents had a clinically signiﬁcant decrease in their level of depression,
whereas 9.3% had a clinically signiﬁcant increase. Additional cluster analyses will
be conducted to identify the characteristics of those parents whose depressive
symptoms changed.
Discussion: Parents of children with CF reported higher rates of depression than
the general population. However, because 20% of parents reported changes in their
symptoms over time, further analyses are needed to understand these processes of
change.
This study was funded by NIH grant #069736.
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Adults with CF face unique challenges during the end-of-life phase, including,
amongst others the ongoing hope for lung transplantation up until the ﬁnal days of
life, yet little research has explored these issues and no CF-speciﬁc, palliative care
(PC) model exists. We aim to explore patient, family and staff experiences related
to end-of-life care. The tool used to collect qualitative data for the model will also
be presented.
Methodology: Interviews were conducted with CF patients (N = 12), bereaved
family members (N = 10) and focus groups of CF and lung transplantation staff
(N = 18).
Results: Patient themes included: lack of knowledge of PC, the view that PC
is seen as “giving up”, responsibility and roles, content and honesty, detachment
from palliative care and transplantation as the solution. Patients felt it was the
responsibility of the CF team to raise discussions about PC but views about when
this should occur varied. Regardless of health status, patients did not see PC as
relevant to them at present.
Bereaved families were satisﬁed with their loved one’s end of life care, though
communication and assistance with practical management were reported issues. For
staff, there were tensions between providing maximum comfort to patients versus
active treatment in the hope of transplantation. Discussions about end-of-life issues
were seen as difﬁcult due to medical uncertainty and the sensitivity of the topic.
These themes are important determinants for the development of an effective model
for palliative care in non-malignant disease, such as CF.
Supported by: The Australian Cystic Fibrosis Trust.
